Sarepta rises after muscle disease drugs show promise in early-to-mid stage trials

Sarepta Therapeutics

25/03/2026 12:18

** Shares of drugmaker Sarepta Therapeutics SRPT.O rise 6.1% to $18.70 premarket

** Co says early-to-mid stage studies of two experimental drugs for rare muscle diseases showed high levels of the treatment reaching muscle tissue with no serious safety issues

** One of the drugs targets facioscapulohumeral muscular dystrophy, a rare inherited disorder that causes progressive muscle weakness, while the other targets myotonic dystrophy type 1, a common adult-onset muscle disorder that can affect the heart and breathing

** Co says the treatments reduced harmful proteins or genetic material linked to the diseases after a single dose

** Adds most side effects were mild to moderate, with no dose-limiting safety signals

** Shares fell ~82% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))